JP2016507526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507526A5 JP2016507526A5 JP2015556185A JP2015556185A JP2016507526A5 JP 2016507526 A5 JP2016507526 A5 JP 2016507526A5 JP 2015556185 A JP2015556185 A JP 2015556185A JP 2015556185 A JP2015556185 A JP 2015556185A JP 2016507526 A5 JP2016507526 A5 JP 2016507526A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sulfasalazine
- composition according
- polymer
- pvp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 claims 11
- 229960001940 Sulfasalazine Drugs 0.000 claims 11
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 7
- 229920003083 Kollidon® VA64 Polymers 0.000 claims 4
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 108009000433 Amyotrophic lateral sclerosis (ALS) Proteins 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 238000010922 spray-dried dispersion Methods 0.000 claims 1
Claims (15)
- スルファサラジンが本質的に非晶質形態である、スルファサラジンおよび医薬的に許容しうるポリマーを含む医薬的に許容しうる賦形剤を含む医薬組成物。
- 神経変性疾患または障害を治療するための、請求項1に記載の医薬組成物。
- 神経変性疾患または障害が、筋萎縮性側索硬化症(ALS)または進行性多発性硬化症(P-MS)である、請求項2に記載の医薬組成物。
- 神経変性疾患または障害が、筋萎縮性側索硬化症(ALS)である、請求項3に記載の医薬組成物。
- 神経変性疾患または障害が、進行性多発性硬化症(P-MS)である、請求項3に記載の医薬組成物。
- スルファサラジンのインビトロ溶解度が、実施例9の方法によって測定される場合、pH5.5において、少なくとも500 μg/mlであるように製剤される、請求項1〜5のいずれか一項に記載の医薬組成物。
- スルファサラジンのインビトロ溶解度が、実施例9の方法によって測定される場合、pH5.5において、約500 μg/ml〜約11,500 μg/ml(両端値も含む)であるように製剤される、請求項1〜5のいずれか一項に記載の医薬組成物。
- 医薬的に許容しうるポリマーが、PVP VA64である、請求項1に記載の医薬組成物。
- 医薬組成物中のスルファサラジン:PVP VA64の比率が、約20:80 wt/wt〜30:70 wt/wtである、請求項8に記載の医薬組成物。
- スルファサラジン:PVP VA64の比率が、約25:75 wt/wtである、請求項9に記載の医薬組成物。
- 医薬組成物が、噴霧乾燥分散体の形状である、請求項1〜10のいずれか一項に記載の医薬組成物。
- スルファサラジンの溶解度を改善する方法であって、20:80 wt/wt〜30:70 wt/wtの範囲のスルファサラジン:ポリマーの重量比で、スルファサラジンが本質的に非晶質形態である、スルファサラジンとポリマーを組み合わせることによって、pHを5.5に調節後1200分測定される場合、pH5.5において、少なくとも500 μg/mlのスルファサラジンのインビトロ溶解度を得ることを含む、方法。
- スルファサラジンのインビトロ溶解度が、pHを5.5に調節後1200分測定される場合、pH5.5において、500 μg/ml〜11,500 μg/ml(両端値も含む)である、請求項12に記載の方法。
- ポリマーが、医薬的に許容しうるポリマーである、請求項13に記載の方法。
- ポリマーが、PVP VA64である、請求項14に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759933P | 2013-02-01 | 2013-02-01 | |
US61/759,933 | 2013-02-01 | ||
US201361780340P | 2013-03-13 | 2013-03-13 | |
US61/780,340 | 2013-03-13 | ||
PCT/US2014/014290 WO2014121137A2 (en) | 2013-02-01 | 2014-01-31 | Compositions and methods for the treatment of neurodegenerative and other diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018079284A Division JP2018123159A (ja) | 2013-02-01 | 2018-04-17 | 神経変性およびその他の疾患の治療用組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016507526A JP2016507526A (ja) | 2016-03-10 |
JP2016507526A5 true JP2016507526A5 (ja) | 2017-02-23 |
JP6328146B2 JP6328146B2 (ja) | 2018-05-23 |
Family
ID=50382538
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015556185A Expired - Fee Related JP6328146B2 (ja) | 2013-02-01 | 2014-01-31 | 神経変性およびその他の疾患の治療用組成物および方法 |
JP2018079284A Pending JP2018123159A (ja) | 2013-02-01 | 2018-04-17 | 神経変性およびその他の疾患の治療用組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018079284A Pending JP2018123159A (ja) | 2013-02-01 | 2018-04-17 | 神経変性およびその他の疾患の治療用組成物および方法 |
Country Status (10)
Country | Link |
---|---|
US (5) | US9597339B2 (ja) |
EP (1) | EP2950797B1 (ja) |
JP (2) | JP6328146B2 (ja) |
KR (1) | KR20150139830A (ja) |
CN (1) | CN105163735B (ja) |
AU (2) | AU2014212109B2 (ja) |
CA (1) | CA2899032A1 (ja) |
ES (1) | ES2752021T3 (ja) |
IL (1) | IL240206A0 (ja) |
WO (1) | WO2014121137A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6328146B2 (ja) * | 2013-02-01 | 2018-05-23 | グリアロジクス・インコーポレイテッドGlialogix, Inc. | 神経変性およびその他の疾患の治療用組成物および方法 |
KR102364840B1 (ko) | 2014-11-05 | 2022-02-18 | 삼성전자주식회사 | 신경세포의 탈수초화와 연관된 질환을 치료하기 위한 약학적 조성물 및 그를 이용하는 방법 |
US20160199393A1 (en) * | 2015-01-08 | 2016-07-14 | China Medical University | Methods of treating brain ischemia or hypoxia |
ES2650175B1 (es) * | 2016-04-15 | 2019-02-04 | Servicio Andaluz De Salud | Tratamiento de enfermedades neurodegenerativas |
US20190343860A1 (en) * | 2016-04-26 | 2019-11-14 | Saint Louis University | Highly selective adenosine a3 receptor subtype agonists for the prevention and treatment of neurodegenerative disorders |
US20180110760A1 (en) | 2016-10-21 | 2018-04-26 | Glialogix, Inc. | Compositions and methods for the treatmentof neurodegenerative and other diseases |
US10473672B2 (en) * | 2017-02-09 | 2019-11-12 | Kaohsiung Chang Gung Memorial Hospital | Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers |
US20230210871A1 (en) * | 2017-10-12 | 2023-07-06 | The Limited Company Research And Development Company "Medbiopharm" | Use of sulfasalazine as an inhibitor of the formation of advanced glycation end products |
JP6603815B2 (ja) | 2017-11-21 | 2019-11-06 | 積水化学工業株式会社 | 皮膚外用剤 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2396145A (en) | 1940-12-14 | 1946-03-05 | Pharmscia Ab | Heterocyclic sulphonamido azo compounds |
FR2608988B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
BR9509171A (pt) | 1994-09-29 | 1997-09-16 | Andaris Ltd | Microparticulas secas por borrifamento como veículos terapêuticos |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
ITMI962356A1 (it) | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
ATE287257T1 (de) | 1997-01-16 | 2005-02-15 | Massachusetts Inst Technology | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
JP2002518432A (ja) | 1998-06-24 | 2002-06-25 | アドバンスト インハレーション リサーチ,インコーポレイテッド | 吸入器から放出される大多孔性粒子 |
AU758351B2 (en) | 1998-08-25 | 2003-03-20 | Alkermes, Inc. | Stable spray-dried protein formulations |
US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
KR100417623B1 (ko) * | 2000-03-28 | 2004-02-05 | 주식회사 뉴로테크 | 뇌질환 예방 및 치료용 조성물 |
CA2307278A1 (en) | 2000-04-28 | 2001-10-28 | University Of British Columbia | Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine |
BR0307333A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização |
BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
EP1824564A4 (en) | 2004-10-27 | 2009-09-16 | Uab Research Foundation | METHOD OF TREATING GLIOMA |
JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス, エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
US20070053869A1 (en) | 2005-09-02 | 2007-03-08 | Yuichi Sugiyama | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents |
EP1983984B1 (en) | 2006-02-02 | 2018-03-07 | Novartis AG | Tuberous sclerosis treatment |
GB0602123D0 (en) * | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
US7964585B2 (en) | 2006-03-14 | 2011-06-21 | Case Western Reserve University | Composition and method of treating peripheral neuropathy |
WO2008027993A2 (en) | 2006-08-31 | 2008-03-06 | Eurand, Inc. | Drug delivery systems comprising solid solutions of weakly basic drugs |
WO2008135828A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
EP2231169B1 (en) | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
MX2010009043A (es) * | 2008-02-28 | 2010-10-25 | Bial Portela & Ca Sa | Composicion farmaceutica para farmacos poco solubles. |
PL2113254T3 (pl) * | 2008-04-28 | 2013-01-31 | Txcell | Kompozycje do leczenia autoimmunologicznego stanu zapalnego |
AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
WO2010111132A2 (en) | 2009-03-27 | 2010-09-30 | Bend Research, Inc. | Spray-drying process |
EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
WO2012031133A2 (en) | 2010-09-03 | 2012-03-08 | Bench Research, Inc. | Spray-drying apparatus and methods of using the same |
US20130202659A1 (en) | 2012-01-31 | 2013-08-08 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
JP6328146B2 (ja) * | 2013-02-01 | 2018-05-23 | グリアロジクス・インコーポレイテッドGlialogix, Inc. | 神経変性およびその他の疾患の治療用組成物および方法 |
CN113209024A (zh) | 2013-12-31 | 2021-08-06 | 阿森迪亚制药有限责任公司 | 疏水性化合物的药物组合物 |
-
2014
- 2014-01-31 JP JP2015556185A patent/JP6328146B2/ja not_active Expired - Fee Related
- 2014-01-31 US US14/170,405 patent/US9597339B2/en active Active
- 2014-01-31 ES ES14712798T patent/ES2752021T3/es active Active
- 2014-01-31 EP EP14712798.9A patent/EP2950797B1/en active Active
- 2014-01-31 CN CN201480019892.8A patent/CN105163735B/zh not_active Expired - Fee Related
- 2014-01-31 CA CA2899032A patent/CA2899032A1/en not_active Abandoned
- 2014-01-31 KR KR1020157023718A patent/KR20150139830A/ko not_active Application Discontinuation
- 2014-01-31 WO PCT/US2014/014290 patent/WO2014121137A2/en active Application Filing
- 2014-01-31 AU AU2014212109A patent/AU2014212109B2/en not_active Ceased
-
2015
- 2015-07-29 IL IL240206A patent/IL240206A0/en unknown
-
2016
- 2016-11-30 US US15/365,835 patent/US9974798B2/en not_active Expired - Fee Related
- 2016-11-30 US US15/365,843 patent/US9980978B2/en not_active Expired - Fee Related
-
2017
- 2017-02-10 US US15/430,294 patent/US9918997B2/en not_active Expired - Fee Related
-
2018
- 2018-04-17 US US15/955,020 patent/US10398713B2/en not_active Expired - Fee Related
- 2018-04-17 JP JP2018079284A patent/JP2018123159A/ja active Pending
- 2018-08-28 AU AU2018222921A patent/AU2018222921A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016507526A5 (ja) | ||
WO2015120110A3 (en) | Novel pharmaceutical formulations | |
WO2015042078A8 (en) | Substituted aminopyrimidine compounds and methods of use | |
MX370853B (es) | Formulaciones que contienen dapagliflozina amorfa. | |
SG190448A1 (en) | Rapidly dispersing granules, orally disintegrating tablets and methods | |
NZ728392A (en) | High dosage strength tablets of rucaparib | |
WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
NZ721952A (en) | Delayed release compositions of linaclotide | |
NZ737945A (en) | Orodispersible dosage unit containing an estetrol component | |
WO2013134047A3 (en) | Aminoquinoline derivatives and uses thereof | |
WO2011025286A3 (ko) | 리포테이코익산 유래 당지질 및 이를 포함하는 조성물 | |
UA117755C2 (uk) | Аморфний летермовір і тверді фармацевтичні препарати, що містять його, призначені для перорального введення | |
MX2017009699A (es) | Composicion de suspension oftalmica. | |
WO2014081581A3 (en) | Highly loaded amorphous efavirenz composition and process for preparing the same | |
WO2016040814A3 (en) | Disulfide polymers and methods of use | |
NZ727834A (en) | Fast acting orally disintegrating film | |
MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
MD4563B1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
WO2012126441A3 (es) | Péptidos cíclicos con actividad antineoplásica y antiangiogénica. | |
JP2016513650A5 (ja) | ||
EP3292872A4 (en) | COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY INFECTIOUS DISEASES OR COMPOSITION FOR ENHANCING IMMUNITY COMPRISING TRYPTOPHANYL-ARNT SYNTHASE AS ACTIVE INGREDIENT | |
NZ767710A (en) | Ocular formulations for drug-delivery and protection of the anterior segment of the eye | |
WO2014142469A3 (ko) | 안과 염증 질환 치료용 점안제 조성물 및 이의 제조 방법 |